Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Robert

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
Breast Cancer Research and Treatment|May 25, 2010
Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpointNicholas J Robert
Clinical Breast Cancer|July 2, 2017
Patient Case Lessons: Endocrine Management of Advanced Breast CancerNicholas J Robert, Neelima Denduluri
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in ChinaNino Balanchivadze, Nicholas J Robert
Hematology/Oncology Clinics of North America|May 22, 2007
HER2-positive advanced breast cancerNicholas J Robert, Anne M Favret
Medgenmed : Medscape General Medicine|December 22, 2005
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancerHenning T Mouridsen, Nicholas J Robert
European Journal of Cancer (Oxford, England : 1990)|August 16, 2005
The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal womenHenning T Mouridsen, Nicholas J Robert
Current Oncology (Toronto, Ont.)|January 20, 2023
Impact of COVID-19 Pandemic on Non-Small Cell Lung Cancer CareYiYuan Zhai, Pooja Chopra, David Kang, et al.
Clinical Lung Cancer|June 30, 2021
Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community OncologistsDavid M Waterhouse, Wan-Yu Tseng, Janet L Espirito, et al.
Journal of Comparative Effectiveness Research|May 29, 2026
Directly comparing randomized and real-world controls in adjuvant breast cancerBrigham Walker, Marley Boyd, Michelle Silver, et al.
Drugs - Real World Outcomes|January 8, 2017
HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and OutcomesNicholas J Robert, Hans-Peter Goertz, Pooja Chopra, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Breast Cancer Research and Treatment|May 25, 2010
Overall survival in metastatic breast cancer: always our quest but not necessarily a primary endpointNicholas J Robert
Clinical Breast Cancer|July 2, 2017
Patient Case Lessons: Endocrine Management of Advanced Breast CancerNicholas J Robert, Neelima Denduluri
Translational Breast Cancer Research : a Journal Focusing on Translational Research in Breast Cancer|May 16, 2024
Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in ChinaNino Balanchivadze, Nicholas J Robert
Hematology/Oncology Clinics of North America|May 22, 2007
HER2-positive advanced breast cancerNicholas J Robert, Anne M Favret
Medgenmed : Medscape General Medicine|December 22, 2005
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancerHenning T Mouridsen, Nicholas J Robert
European Journal of Cancer (Oxford, England : 1990)|August 16, 2005
The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal womenHenning T Mouridsen, Nicholas J Robert
Current Oncology (Toronto, Ont.)|January 20, 2023
Impact of COVID-19 Pandemic on Non-Small Cell Lung Cancer CareYiYuan Zhai, Pooja Chopra, David Kang, et al.
Clinical Lung Cancer|June 30, 2021
Understanding Contemporary Molecular Biomarker Testing Rates and Trends for Metastatic NSCLC Among Community OncologistsDavid M Waterhouse, Wan-Yu Tseng, Janet L Espirito, et al.
Journal of Comparative Effectiveness Research|May 29, 2026
Directly comparing randomized and real-world controls in adjuvant breast cancerBrigham Walker, Marley Boyd, Michelle Silver, et al.
Drugs - Real World Outcomes|January 8, 2017
HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and OutcomesNicholas J Robert, Hans-Peter Goertz, Pooja Chopra, et al.
Pageof 6